Galpin J, Thompkins J, Abels R, Turpen TJ; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 276 (abstract no. M.B.P.328).

Porton Medical Group, Sherman Oaks, CA, USA

OBJECTIVE: To determine if anemic AIDS patients who are all on concomitant zidovudine therapy and are transfusion-dependent have any measurable change in their hematocrit, hemoglobin and reticulocyte count after treatment with r-HuEPO. METHODS: Nine evaluable subjects with a pretreatment hematocrit of 30% or less were treated with ascending doses of r-HuEPO up to 900 u/kg weekly for 24 weeks. Patients were on daily doses of zidovudine of 400 to 4200 mg. The hematocrit, hemoglobin and reticulocyte count were obtained on a weekly basis. RESULTS: All but one subject attained a hematocrit of 38-40% during the 24 week trial, becoming transfusion-independent. CONCLUSIONS: r-HuEPO appears to be a possible adjunctive therapy for AIDS patients who are anemic due to their disease and zidovudine therapy. This drug merits further wide-scale clinical trials.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Anemia
• Animals
• Blood Transfusion
• Erythrocyte Transfusion
• Erythropoietin, Recombinant
• Hematocrit
• Hemoglobins
• Humans
• Reticulocyte Count
• Safety
• Zidovudine
• therapy

Other ID:

• 00129189

UI: 102177182

From Meeting Abstracts